Study of ImmuNology in Antibody Positive PsychosiS (SINAPPS)

Feasibility Study - SINAPPS-1

Feasibility and acceptability of immunotherapy in antibody positive FEP 

 

We are developing a completely new approach to the investigation and treatment of people with the major neuropsychiatric disorder, schizophrenia. SINAPPS group aims to treat people who test positive for NMDAR (and other similar) antibodies in a similar way to people diagnosed with autoimmune encephalitis, using immunological methods.

The SINAPPS-1 study aims at determining which treatment is considered by participants as the most acceptable and least invasive, while still being effective in removing pathogenic antibodies.

 

These findings will then be applied in the SINAPPS 2 study.

 

SINAPPS 1 completed recruitment on July 2017.

 

 

This study was funded by the Stanley Medical Research Institute.

 

SINAPPS1_squarelogo_use SMRI

Clinical Trial - SINAPPS-2

A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis

 

The SINAPP2 randomized clinical trial will investigate the use of Intravenous Immunoglobulin (IVIG) and Rituximab as a treatment for symptoms of psychosis in antibody positive patients. The study will take place in 8 different sites across England to make it accessible to as many participants as possible.

 

Recruitment began in July 2017 and the study will run until 2021.

 

Click here for more information.

 

 

 

This trial is funded by the Medical Research Council.

mrc

SINAPPS-1 was a feasibility study, involving a very small number of patients. In this study we aimed to identify the most acceptable treatment to eliminate pathogenic antibodies.

 

SINAPPS-2 is a larger study involving participants from all across England, testing the efficacy and safety of immunotherapy in persons suffering from antibody-induced symptoms of psychosis.

 

 

SINAPPS_JH_logo_4

 

Social Media

You can keep up to date with our studies by following us on social media

Twitter square blue large Facebook square blue large